Saturday, November 18, 2017
Tailwinds' Take: Once funded, expect the good news to roll for 3DS. This company has a unique technology with many opportunities to partner on developing products. We recently doubled our weighting at this deal price and think the placement...
Tailwinds' Take: the first good news for 3DS in a while comes shortly after the arrival of a strategic investor into the Company. Hidden at the end of this release is a patent for Alzheimers as well. 3DS has...
Tailwinds' Take: this is a key endorsement as the Company looks to lock up more financing. Once they are funded, there should be a nice pathway towards clinical success in the not too distant future. TORONTO, Oct. 03, 2017 (GLOBE...
3D Signatures has been trying to raise money for months. To date, they have not been successful. I think that will change soon as there is too much value here to be ignored. Meanwhile, the fact that the management...
TORONTO, ON (June 8, 2017) − 3D Signatures Inc. (TSXV:DXD; OTCQB:TDSGF; FSE:3D0) (the "Company" or "3DS"), is pleased to announce that the clinical trial component (the “Clinical Trial”) of its Hodgkin’s lymphoma (“HL”) test (“Telo-HL”) validation program is successfully...
Tailwinds' Take: 3DS accomplished a lot this last quarter, but the bigger catalysts should be coming in the second half of this year as the company advances on several fronts. TORONTO, May 31, 2017 (GLOBE NEWSWIRE) -- 3D Signatures Inc. (TSXV:DXD)...
Tailwinds Take: a well written article by David Templeton of the Pittsburgh Post-Gazette that discusses the work of Dr. Sabine Mai in conjunction with Dr. Hans Knecht on the use of telomeres in cancer diagnostics. Discovery, the goal of science,...
3D Signatures is using telomeres to help diagnose many forms of cancer, including prostate. Hear what they're doing in prostate as well as catalysts for the rest of the year, in this video with CEO Jason Flowerday.
As CEO of 3D Signatures (OTCQB:TDSGF; TSXV:DXD; FSE:3D0) since last September, Jason Flowerday is putting the diagnostic company on people’s radar. Unlike most diagnostic companies, 3DS’ proprietary imaging software, known as TeloView, goes beyond identifying whether a patient suffers...
Tailwinds' Take: This is a major milestone for 3DS as PRECISE is the first ever large-scale multi-center study focused on men with a clinical suspicion of prostate cancer. It serves to validate their diagnostic technology among potential prostate cancer patients, a huge...
Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address